274 related articles for article (PubMed ID: 15207740)
1. Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures.
Igarashi K; Hirotani H; Woo JT; Stern PH
Bone; 2004 Jul; 35(1):47-56. PubMed ID: 15207740
[TBL] [Abstract][Full Text] [Related]
2. The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand.
Shui C; Riggs BL; Khosla S
Calcif Tissue Int; 2002 Nov; 71(5):437-46. PubMed ID: 12202955
[TBL] [Abstract][Full Text] [Related]
3. Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures.
Otsuka T; Kasai H; Yamaguchi K; Nishihara T
J Dent; 2005 Oct; 33(9):749-55. PubMed ID: 16199283
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms.
Granholm S; Lundberg P; Lerner UH
J Endocrinol; 2007 Dec; 195(3):415-27. PubMed ID: 18000304
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.
Miyazaki M; Fujikawa Y; Takita C; Tsumura H
Clin Rheumatol; 2007 Feb; 26(2):231-9. PubMed ID: 16586042
[TBL] [Abstract][Full Text] [Related]
6. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
Glantschnig H; Fisher JE; Wesolowski G; Rodan GA; Reszka AA
Cell Death Differ; 2003 Oct; 10(10):1165-77. PubMed ID: 14502240
[TBL] [Abstract][Full Text] [Related]
7. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
[TBL] [Abstract][Full Text] [Related]
9. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
10. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts.
Woo JT; Nakagawa H; Notoya M; Yonezawa T; Udagawa N; Lee IS; Ohnishi M; Hagiwara H; Nagai K
Biol Pharm Bull; 2004 Apr; 27(4):504-9. PubMed ID: 15056855
[TBL] [Abstract][Full Text] [Related]
11. Effects of the phytoestrogen coumestrol on RANK-ligand-induced differentiation of osteoclasts.
Kanno S; Hirano S; Kayama F
Toxicology; 2004 Oct; 203(1-3):211-20. PubMed ID: 15363596
[TBL] [Abstract][Full Text] [Related]
12. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
13. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro.
Tomita M; Li X; Okada Y; Woodiel FN; Young RN; Pilbeam CC; Raisz LG
Bone; 2002 Jan; 30(1):159-63. PubMed ID: 11792579
[TBL] [Abstract][Full Text] [Related]
14. High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture.
Takahashi E; Mukohyama H; Aoki K; Duarte WR; Lerner UH; Ohya K; Omura K; Kasugai S
J Med Dent Sci; 2002 Dec; 49(4):109-20. PubMed ID: 12641381
[TBL] [Abstract][Full Text] [Related]
15. Role of ascorbic acid in the osteoclast formation: induction of osteoclast differentiation factor with formation of the extracellular collagen matrix.
Otsuka E; Kato Y; Hirose S; Hagiwara H
Endocrinology; 2000 Aug; 141(8):3006-11. PubMed ID: 10919289
[TBL] [Abstract][Full Text] [Related]
16. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.
Lee SK; Kalinowski JF; Jastrzebski SL; Puddington L; Lorenzo JA
Endocrinology; 2003 Aug; 144(8):3524-31. PubMed ID: 12865334
[TBL] [Abstract][Full Text] [Related]
18. Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin.
Lee SK; Goldring SR; Lorenzo JA
Endocrinology; 1995 Oct; 136(10):4572-81. PubMed ID: 7664679
[TBL] [Abstract][Full Text] [Related]
19. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL).
Suzuki T; Suda N; Ohyama K
J Bone Miner Metab; 2004; 22(3):185-91. PubMed ID: 15108059
[TBL] [Abstract][Full Text] [Related]
20. Self-assembled RANK induces osteoclastogenesis ligand-independently.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 Nov; 20(11):2053-60. PubMed ID: 16234979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
